Medications for Opioid Use Disorder
1)

According to the American Society of Addiction Medicine, Addiction is known as 
 
According to the American Society of Addiction Medicine, Addiction is known as A primary, chronic disease of brain reward, motivation, memory, and related circuitry A factor of PTSD The result of Trauma
 
2)

Opioids is known as
 
Any natural medicine Any herbs All natural, synthetic, and semisynthetic substances that have effects similar to morphine. Any medicinal tablets
 
3)

OTP is an acronym for
 
Opioid Treatment Program Opioid Treatment Pattern Opioid Training Program Opioid Training Pattern
 
4)

According to DMS-5, Opioid Use Disorder or OUD is 
 
Is any substance that has effect similar to morphine Is a disorder Is not a disorder A disorder characterized by loss of control of opioid use, risky opioid use, impaired social functioning, tolerance, and withdrawal.
 
5)

Remission is known as 
 
A medical term for the symptoms of OUD A medical term meaning a disappearance of signs and symptoms of the disease. The other term for relapse Addiction per se
 
6)

The FDA-approved medications for reducing or eliminating withdrawal symptoms are
 
Naltrexone and Paracetamol Ibuprofen and Naltrexone Paracetamol and methadone Methadone and buprenorphine
 
7)

Methadone retains patients in treatment and reduces illicit opioid use more effectively than placebo, medically supervised withdrawal, or no treatment, as numerous clinical trials and meta-analyses of studies conducted in many countries show.
 
True False
 
8)

“Maintenance Treatment” is an approach
 
When a patient receives medication for as long as it provides a benefit. When a patient does not receive any medication at all When a medication modifies the patient’s attitudes and behaviors related to drugs Increases healthy lifestyle
 
9)

Medically supervised withdrawal is a process in a which
 
That alters the mood and perception Providers offer methadone or buprenorphine on a short-term basis to reduce physical withdrawal signs and symptoms. Providers offer a short-term treatment plan Reverse or reduce risk factors
 
10)

Medical Management is a process 
 
Whereby healthcare professionals provide medication, basic brief supportive counseling, monitoring of drug use and medication adherence, and referrals, when necessary, to addiction counseling and other services to address the patient’s medical, ment That minimizes cravings and withdrawals That uses medicines at the beginning of the treatment only Of denial or resistance
 
11)

Office-based Opioid Treatment (OBOT) is 
 
The same as medical management A behavioral therapy Staying in the treatment longer Medication for OUD in outpatient settings other than certified opioid treatment programs (OTPs).
 
12)

Opioid Receptor Agonist is 
 
A substance for compulsion and cravings A substance that regulates drug cravings A substance that has an affinity for and stimulates physiological activity at cell receptors in the central nervous system that are normally stimulated by opioids. A substance that minimizes cravings and withdrawal symptoms.
 
13)

Opioid Receptor Antagonist is 
 
A substance that has an affinity for opioid receptors in the central nervous system without producing the physiological effects of opioid agonists. A substance that makes the person uncoordinated and sleepy A substance that increases the drug abuse A substance that makes the patient unproductive and disoriented
 
14)

Appropriate treatment intensity depends on each patient’s
 
Social circumstances, severity of addiction, personal preferences, psychiatric/psychological needs, and ability to afford treatment at a given intensity Social circumstances and severity of addiction only Severity of addiction and personal preferences only Psychological needs and social circumstances only
 
15)

Induction is defined as the 
 
Process of being physically fit Process of staying drug-free Recurrent legal problems from substance abuse Process of initial dosing with medication for OUD treatment until the patient reaches a state of stability; also called initiation.
 
16)

Cross-tolerance is known as 
 
Potential for people tolerant to one opioid (e.g., heroin) to be tolerant to another (e.g., methadone). Opioid Receptor Antagonist Opioid Receptor Agonist Office-based Opioid Treatment (OBOT)
 
17)

Opiates are
 
Kinds of Cognitive-Behavioral Therapy The kinds of behavioral therapy Subclass of opioids derived from opium (e.g., morphine, codeine, thebaine). Substances that minimize cravings and withdrawal symptoms.
 
18)

Opioid receptor agonist is defined as the
 
Recurrent legal problems from substance abuse Reverse or reducing the risk factors Office-based Opioid Treatment (OBOT) Substance that has an affinity for and stimulates physiological activity at cell receptors in the nervous system that are normally stimulated by opioids.
 
19)

Extended-release naltrexone (XR-NTX) is FDA approved to
 
Prevent relapse in patients who have remained opioid abstinent for sufficient time. Encourage relapse in patients who have remained opioid abstinent for sufficient time. Have a healthy lifestyle Reduced risk factors
 
20)

Several factors underlie the development of addiction involving opioids and the difficulty people have in achieving and maintaining abstinence from them. These factors include:
 
Geographic and socio-economic status Short-term direct & indirect mu-opioid receptor agonist effects, neuroplastic changes in the brain, and genetic, developmental, and environmental changes Short-term direct & indirect mu-opioid receptor agonist effects and neuroplastic changes in the brain only Neuroplastic changes in the brain and environmental changes
 
21)

There are several formulations of methadone. These are
 
Liquid concentrate and tablets only Liquid concentrate, powder, dispersible tablets, and tablets Liquid concentrate and powder only Dispersible tablets and tablets only
 
22)

QTc prolongation is an
 
Abnormally long time in electrocardiogram (ECG) tracing between the start of a Q wave and the end of a T wave. Normally long time in electrocardiogram (ECG) tracing between the start of a Q wave and the end of a T wave. FDA black box warning Rare ventricular arrhythmia
 
23)

NAS is an acronym for 
 
Neonatal Abstinence System Neonatal Absence System Neonatal Abstinence Syndrome Natural Abstinence Syndrome
 
24)

Possible side effects of methadone include 
 
Constipation and weight gain Constipation, Nausea, Sweating, Sexual Dysfunction, Drowsiness, Amenorrhea, Weight gain, and Edema Constipation and Nausea Sweating and decreased libido
 
25)

Before patients should give their consent, they should be informed of
 
Their OUD diagnosis and the nature of the disorder Risks and benefits of methadone Risks and benefits of nonmedication treatments Their OUD diagnosis and the nature of the disorder, risks and benefits of methadone and other OUD medications, and risks and benefits of nonmedication treatments.
 
26)

Take-Home Medication provides
 
Non-incentive feeling for patients in achieving the treatment goals A powerful incentive for patients to achieve treatment goals. Reduction in risk factors An increase in risk factors
 
27)

Leaving Methadone Treatment is associated with 
 
Increased risk of death from overdose and other causes. Decreased risk of death from overdose and other causes. Balanced risk of death from overdose and other causes. Imbalance risk of death from overdose and other causes.
 
28)

Discuss risks and benefits with patients who wish to discontinue treatment by exploring their reasons foe wanting to discontinue treatment. These reasons may include
 
Side effects and logistics Side effects and costs Logistics, Costs, Side effects, opinion if friends or family, and a desire to switch to buprenorphine or XR-NTX treatment. Logistics and costs only
 
29)

Naltrexone does
 
Not activate the mu-opioid receptor and exerts no opioid effects. Activate the mu-opioid receptor and exerts no opioid effects. Alleviate withdrawal symptoms Cause withdrawal when stopped, and cannot be diverted.
 
30)

XR-NTX is indicated for
 
The prevention of return to opioid dependence following medically supervised opioid withdrawal The non-prevention of return to opioid dependence following medically supervised opioid withdrawal Opioid withdrawal Opioid dependence
 
31)

Possible side effects of XR-NTX include
 
Injection site pain and Insomnia Insomnia, injection site pain, hepatic enzyme abnormalities, and nasopharyngitis Insomnia and PTSD PTSD and Trauma
 
32)

The signs for Opioid Withdrawal are
 
Runny nose, tearing, yawning, sweating, tremor, vomiting, piloerection, and pupillary dilation Vomiting and runny nose only Yawning and vomiting only Sweating and tremor only
 
33)

The symptoms for Opioid Withdrawal are
 
Abnormal cramps and temperature changes only Skin crawling, abnormal cramps, temperature changes, nausea, vomiting, diarrhea, bone or muscle pain, dysphoria, and craving for opioids Nausea and vomiting only Diarrhea and muscle pain only
 
34)

The signs that a patient may be ready to discontinue XR-NTX medication include
 
Sustaining illicit drug abstinence over time Legal problems Sustaining illicit drug abstinence over time, having stable housing and income, having no legal problems, having sustainability reduced craving, and attending counseling or mutual-help groups Relapse
 
35)

Patients can successfully initiate XR-NTX in a general outpatient medical setting if they
 
Have been abstinent for sufficient time and pass naloxone challenge, and started taking XR-NTX elsewhere and are due for the next injection. Have been abstinent for sufficient time only Having passed the naloxone challenge only Started taking XR-NTX elsewhere
 
36)

Opioid treatment programs (OTPs) may administer or dispense buprenorphine, but only providers with Substance Abuse and Mental Health Services Administration (SAMHSA) waivers can prescribe buprenorphine for OUD.
 
True False
 
37)

Through cross-tolerance and mu-opioid receptor occupancy, at adequate doses, buprenorphine..
 
Decreases relapse possibility Increases relapse possibility Reduces opioid withdrawal and craving and blunts the effects of illicit opioids. Increases opioid withdrawal and craving and blunts the effects of illicit opioids.
 
38)

FDA warns of increased serotonin syndrome risk with prescription opioids, including buprenorphine. Serotonin syndrome can include
 
Depression Trauma PTSD Changes in mental status, fever, tremor, sweating, and dilated pupils
 
39)

Buprenorphine’s side effects may be less intense than those of full agonists. Otherwise, they resemble those of other mu-opioid agonists. Possible side effects include
 
Oral hypoesthesia (oral numbness), constipation, and vomiting Trauma PTSD Bipolar
 
40)

Stabilization occurs when there is evidence of: 
 
Relapse Markedly reduced or eliminated illicit opioid use, reduced craving, suppression of opioid withdrawal, minimal side effects, and patient-oriented blunted or blocked euphoria during illicit opioid use PTSD Trauma
 
41)

Typical maintenance doses range from 4 mg/1 mg to 24 mg/6 mg per day. An effective maintenance dose is the lowest dose that can
 
Eliminate withdrawal, reduce or eliminate opioid craving, reduce or stop illicit opioid use’s desirable effects, and be well tolerated Increase the possibility of relapse Decrease recovery Increase opioid dependency
 
42)

The goal of buprenorphine treatment is
 
Substance Abuse Full remission from OUD. Maintaining illicit opioid use Relapse
 
43)

Psychosocial Support is 
 
Financial Support Educational Support Ancillary services to enhance a patient’s overall functioning and well-being, including recovery support services, case management, housing, employment, and educational services. Support system
 
44)

Psychosocial treatment is known as 
 
side effects of XR-NTX Interventions that seek to enhance patient’s social and mental functioning, including addiction counseling, contingency Sustaining illicit drug abstinence over time Opioid withdrawal and craving and blunts the effects of illicit opioids
 
45)

Components of the management approach include
 
Length and frequency of office visits only Length of time between prescriptions or XR-NTX injections only Medical treatments and referrals only Length and frequency of office visits, length of time between prescriptions or XR-NTX injections, frequency of drug testing, and Ancillary psychosocial and medical treatments and referrals.